By playing, you agree to uListen's Terms and Privacy Policy and YouTube's Terms of Service.
Peter Attia MD230 ‒ Cardiovascular disease in women: prevention, risk factors, lipids, and more
Summaries, chapters, transcripts, and FAQs on this page are made by uListen, not YouTube.
CHAPTERS
- 0:11 – 6:28
Erin Michos's Path into Preventive Cardiology
Peter Attia introduces Erin Michos and the episode's focus on cardiovascular disease and lipids through female biology. The two compare their Hopkins training, and Erin explains how she moved from molecular biology into cardiology and why prevention drew her.
- •Overview of topics: lifetime ASCVD risk, lipids, pregnancy, menopause, PCOS, contraceptives, statins, HRT
- •Erin trained at Hopkins and did a four-year cardiology fellowship emphasizing research
- •She was drawn to cardiology through interest in diet, nutrition, exercise, and lifestyle
- •She cites INTERHEART data that over 90% of MI risk is due to preventable risk factors
- 6:28 – 13:27
Reversing Trends in Women's Heart Disease Mortality
Erin describes how cardiovascular mortality declined after statins and risk-factor treatment but is now rising, especially in younger and middle-aged women. They discuss the cancer comparison, falling awareness among women, and the lingering idea that heart disease is a man's disease.
- •Heart disease death rates are rising fastest in women aged 45 to 64
- •Her study found heart disease mortality in women under 65 rising about 0.5% per year since 2010 while cancer mortality falls
- •AHA survey: awareness that heart disease is the leading killer fell from 65% in 2009 to 44% in 2019
- •Women are under-enrolled in trials and clinicians perceive them as lower risk, leading to undertreatment
- •In FH, women have the same early onset as men and lose their premenopausal advantage
- 13:27 – 21:43
Why Lifetime Risk and Early Prevention Matter
The conversation turns to the cardiovascular risk of women under 65 and the importance of cumulative LDL exposure. Peter uses the area-under-the-curve and retirement-savings analogies, and both argue that treating young adults based on 10-year risk is a mistake.
- •Roughly half of men's and a third of women's major events occur before 65, per the figures Peter cites
- •Duration of LDL exposure matters, not just magnitude
- •Peter explains apoB exposure with calculus and compound-savings analogies
- •Young adults with high blood pressure are treated, yet equivalent lipid elevation often is not
- •Trials rely on short follow-up, so young low-risk people are not studied
- 21:43 – 26:53
ApoB Causality, Risk Scores, and Calcium Scoring
Peter argues that apoB has the same causal standing as smoking and blood pressure yet is treated with a double standard. Erin agrees on causality, explains how the 2019 guidelines handle 10-year risk, risk enhancers, and calcium scoring, and both discuss the limits of a zero calcium score in younger people.
- •LDL meets the criteria for causality through observational, genetic, and interventional evidence
- •No randomized trial enrolled people on the basis of a 10-year risk cut point
- •2019 guidelines acknowledge limitations of risk scores and list risk enhancers including lipoprotein(a) and female-specific factors
- •A zero calcium score is less reassuring in young adults because plaque takes time to calcify
- •Peter notes CTA can find plaque missed by calcium scoring
- 26:53 – 33:42
Treatment Inertia and the Metabolic Health Epidemic
Erin says stalled progress reflects both undertreatment and worsening cardiometabolic health. She cites registry data showing most high-risk patients are not at LDL goal, and discusses obesity, food environments, and population-level drivers.
- •In the GOLD registry, over two-thirds of ASCVD patients stayed above LDL 70 and few had therapy intensified
- •PCSK9 inhibitor use was about 6% in that cohort
- •Obesity, diabetes, and gestational diabetes are rising
- •Erin stresses societal drivers: processed food, food deserts, sedentary work, stress
- •Modest weight loss improves triglycerides and blood pressure
- 33:42 – 37:15
GLP-1 Agonists and Dual Agonists for Obesity
Erin explains semaglutide and tirzepatide, including their approved indications and weight-loss results. She and Peter discuss possible mechanisms for cardiovascular benefit beyond glucose lowering.
- •Semaglutide has cardiovascular outcome data in type 2 diabetes for the injectable form
- •Tirzepatide is a dual GIP/GLP-1 agonist with weight loss up to about 50 pounds at the highest dose
- •MACE benefit is independent of A1C lowering
- •Possible mechanisms include blood pressure, weight, lipids, inflammation, and kidney effects
- 37:15 – 47:14
Female Physiology, Sex Hormones, and the Menstrual Cycle
Erin outlines female-specific risk factors across the lifespan, then explains puberty, menarche, and how lipids fluctuate across the menstrual cycle. She recommends measuring lipids at a consistent point, such as during menses, and the two discuss the roughly ten-year offset in risk.
- •Female-specific risk factors include early or late menarche, PCOS, pregnancy loss, preeclampsia, and early menopause
- •Women also have more inflammatory disease, microvascular dysfunction, SCAD, and stress cardiomyopathy
- •Total cholesterol and LDL peak in the follicular phase and fall in the luteal phase, differing by about 10 mg/dL
- •Peter's practice uses day five for hormone and lipid testing
- •The 10-year offset does not apply in FH or diabetes
- 47:14 – 58:54
PCOS, Parity, and Oral Contraceptives
Erin explains PCOS prevalence, insulin resistance, and cardiovascular risk, then covers pregnancy complications and possible treatments. The discussion extends to grand multiparity and how different contraceptive types affect lipids.
- •PCOS affects roughly 5 to 13% of women and is driven by insulin resistance
- •Her meta-analysis found twofold higher odds of coronary calcium in PCOS
- •PCOS pregnancies carry higher risk of preeclampsia and gestational diabetes
- •High parity shows a J-shaped relationship with CVD; Peter suspects confounding, and Erin notes the risk is a bit greater in women than men
- •Higher-estrogen oral contraceptives can raise triglycerides; IUDs and implants are preferred in FH or ASCVD
- 58:54 – 1:09:50
Lipid Changes During Pregnancy and Familial Hypercholesterolemia
Erin describes the normal rise in lipids during pregnancy, which falls after delivery. The conversation then defines FH, its prevalence and risk, genetic testing, and the undertreatment of women with FH.
- •Total cholesterol, triglycerides, and LDL rise substantially, peaking in the third trimester
- •Pregnancy is not a good time to get a baseline lipid panel
- •FH affects about 1 in 250; 30% of untreated women with FH have an MI before 60
- •Genetic testing adds risk information beyond LDL and enables cascade screening
- •Estrogen-containing contraception should be avoided in FH, with IUDs preferred
- 1:09:50 – 1:16:11
Statins in Pregnancy and Statin Hesitancy in Women
Erin explains why statin concerns in pregnancy led to undertreatment and how the FDA label change offers flexibility. She also covers the trial of statins for preeclampsia prevention, evidence that statins work equally in women, and the role of the nocebo effect.
- •Statins are probably not teratogenic, but most women still stop them during conception, pregnancy, and breastfeeding
- •A trial is testing pravastatin started around 12 weeks to prevent preeclampsia
- •Meta-analysis shows statins benefit women in primary and secondary prevention without sex interaction
- •Women are less likely to be offered statins and more likely to decline or stop them
- •The SAMSON trial found up to 90% of statin-associated symptoms were also elicited by placebo
- 1:16:11 – 1:31:47
Erin's Statin Strategy and Non-Statin Therapies
Peter asks about Erin's statin workflow. She explains aggressive combination therapy in very high-risk patients and rosuvastatin starts in lower-risk ones, then reviews PCSK9 monoclonal antibodies, inclisiran, and bempedoic acid with attention to women.
- •Very high-risk patients start with high-intensity statin and early combination therapy, aiming for LDL below 55
- •Rosuvastatin is a favored first agent; low doses can build trust in hesitant patients
- •Evolocumab and alirocumab lower LDL 50 to 60% with similar benefit in women
- •Inclisiran is a twice-yearly siRNA injection awaiting outcome data
- •Bempedoic acid avoids muscle symptoms and may lower LDL slightly more in women
- 1:31:47 – 1:41:19
Diet, Exercise, Stress, and the Pillars of Prevention
They discuss how much diet can change lipids given the strong genetic component. Erin recommends a Mediterranean-style pattern, exercise, and attention to mental health, while Peter argues nutrition is the lowest-impact of five pillars for cardiovascular disease.
- •About 75 to 80% of LDL is synthesized by the liver, so genetics dominates
- •Erin recommends a Mediterranean-style diet, more unsaturated fats, and fewer processed foods
- •Peter's review of Cochrane meta-analyses left him doubtful that saturated fat restriction matters once in energy balance
- •Stress acts through indirect behaviors and direct mechanisms like sympathetic activation and inflammation
- •Peter ranks nutrition lowest among nutrition, exercise, sleep, emotional health, and pharmacotherapy
- 1:41:19 – 1:50:28
Lipoprotein(a) in Women and Emerging Lp(a) Therapies
Erin recaps Lp(a) structure and how it differs by sex, rising after menopause and doubling in pregnancy. She reviews its causal role, the limits of current therapies, and the pending outcome trials of antisense and siRNA agents.
- •Lp(a) is about 5 to 10% higher in women and rises after menopause
- •It is causally linked to ASCVD and aortic stenosis, with risk even when LDL is low
- •PCSK9 inhibitors lower Lp(a) about 20 to 25%; statins, ezetimibe, and bempedoic acid do not
- •Pelacarsen and olpasiran can lower Lp(a) by 80 to 90%, but outcomes data are awaited
- •Patients with the greatest Lp(a) reduction in FOURIER and ODYSSEY had the greatest MACE reduction in post-hoc analyses
- 1:50:28 – 1:55:35
Menopause and Cardiovascular Risk
Peter asks why menopause accelerates ASCVD risk. Erin explains the estrogen drop, relative androgen excess, visceral fat gain, and the abrupt lipid rise after the final menstrual period.
- •Perimenopause can last years; early menopause raises cardiovascular risk
- •Postmenopausal women have lower estrogen than men
- •Higher testosterone-to-estrogen ratios in her MESA research were linked to more ASCVD and heart failure
- •Blood pressure and diabetes risk track aging, whereas lipid changes track the ovarian effect
- •Menopause brings visceral fat, insulin resistance, and dyslipidemia
- 1:55:35 – 2:03:32
Hormone Therapy Decisions After Menopause
Erin weighs the favorable and unfavorable effects of estrogen and explains why guidelines don't recommend HRT for cardiovascular prevention. She describes how she selects candidates for symptom relief, and Peter frames HRT as a tool for brain, bone, and symptom benefits where heart health is addressed separately.
- •Estrogen lowers LDL and dilates vessels but raises CRP, triglycerides, and clotting risk
- •WHI participants were around 63 and far from menopause; sub-analyses of younger women showed less harm
- •Consider HRT for symptomatic women under 60 or within 10 years of menopause
- •Avoid oral estrogen with CVD, clots, high triglycerides, gallbladder disease, or prior breast or endometrial cancer
- •Erin uses coronary calcium scoring when risk is uncertain; vaginal estrogen is fine for genitourinary symptoms
- 2:03:32 – 2:09:54
Women's Representation in Cardiovascular Trials
Peter asks whether women are being enrolled equally in cardiovascular trials. Erin shares data on persistent underrepresentation, lack of women in trial leadership, and ideas for improving enrollment and design.
- •Women made up about 29% of lipid-lowering trial participants from 1990 to 2018
- •Only about 10% of leadership committees in major trials were women, and over half had none
- •More women authors correlates with higher enrollment of women
- •Remedies include diverse teams, patient-centered and flexible follow-up designs, and fewer restrictive exclusions
- •More trials in pregnant women are needed
- 2:09:54 – 2:15:04
Erin's Marathon Goal and Closing
Peter asks about Erin's marathon running. She describes her goal of running one in every state, her COVID setback, and her upcoming New Jersey marathon, then the episode closes with thanks.
- •Erin has run about 38 marathons across roughly 36 states
- •COVID canceled her planned races and disrupted her running habit
- •She is registered for a New Jersey marathon to pursue state number 37
- •She runs for social support and enjoyment rather than speed
